Navigation Links
HemaQuest Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Study of HQK-1001 in Patients With Sickle Cell Disease
Date:4/25/2011

SAN DIEGO, April 25, 2011 /PRNewswire/ -- HemaQuest Pharmaceuticals, Inc. (HemaQuest), a biotechnology company focused on developing small molecule therapeutics to treat hemoglobin disorders, announced today that clinical investigators have enrolled the first patient in a randomized multi-dose Phase 2 study of HQK-1001 in patients with sickle cell disease. The study, which is being conducted by investigators in clinical sites in the US, Canada, Jamaica, Egypt and Lebanon, is expected to enroll approximately 50 patients. The primary objective is safety and tolerability of HQK-1001. There are several secondary objectives including an increase in fetal hemoglobin production. HemaQuest expects interim results from the study in late 2011 and final results in the first quarter of 2012.

"Based on the promising results from our prior Phase 2 clinical studies, we are excited to initiate this clinical study testing higher dose levels and longer duration of therapy to more fully characterize the therapeutic potential of HQK-1001 in sickle cell disease," said HemaQuest Chief Medical Officer Richard G. Ghalie, MD. "This is an important next step toward potentially making HQK-1001 available as a treatment for this devastating disease in underserved populations around the world."

ABOUT HQK-1001 HQK-1001 belongs to a class of compounds originally discovered at Boston University School of Medicine. These compounds, designated as Short Chain Fatty Acid Derivatives (SCFADs), have been shown to stimulate fetal hemoglobin expression and red blood cell production in the laboratory and in small clinical trials in patients with hemoglobin disorders, including sickle cell disease and beta thalassemia.  Increased fetal hemoglobin production in red blood cells has been shown to reduce the frequency of pain crises and hospitalizations  of patients with sickle cell disease  HQK-1001 is an orally administered SCFAD, which has shown an excellent safety profile a
'/>"/>

SOURCE HemaQuest Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. HemaQuest Pharmaceuticals Raises Additional $4M to Bring Total to $16M in Series B Financing
2. HemaQuest Announces Appointment of New Executive Management Team; Company Establishes Headquarters in San Diego
3. HemaQuest Pharmaceuticals, Inc. Presents Promising Clinical Results at 52nd Annual Meeting of the American Society of Hematology (ASH)
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... N.Y. , Aug. 3, 2015 Par ... a conference call on Friday, August 7, 2015 at ... for the second quarter ended June 30, 2015.  Par ... available to the public in its filings with the ... information available on its website by following the instructions ...
(Date:8/3/2015)...   ConvergeHEALTH by Deloitte is announcing ... is expanding its year-long research collaboration with ... to include women,s health.  This ... generate real-world clinical insights in an effort to ... to expanding our work with Allergan to address ...
(Date:8/3/2015)... 2015 VWR (NASDAQ: VWR ), ... announces the redesign of its global website, www.vwr.com , ... visiting the new site, guests will enjoy enhanced content on ... images.  Each country site now includes: , ... menu; and , the ability to search by discipline/industry. ...
Breaking Medicine Technology:ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 2ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 3ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 4VWR's New Website Redesign Provides Improved Functionality for Customers 2
... TUSTIN, Calif., Jan. 6, 2012 Radient Pharmaceuticals Corporation ... Vitro Diagnostic (IVD) cancer tests, today announced that ... will be launched with a print ad that ... throughout 2012.  These journals have high circulation among ...
... WAYNE, N.J., Jan. 6, 2012  Cascade Medical ... proprietary platelet-rich plasma (PRP) and platelet-rich fibrin matrix (PRFM) ... tissue and bone repair, announced the sale of their ... ConMed Linvatec for the worldwide orthopedic, dental, and wound ...
Cached Medicine Technology:Radient Pharmaceuticals Announces New Advertisement for Oncology Publications 2Cascade Medical Enterprises, LLC Announces the Sale of Their Orthopedic Business 2
(Date:8/3/2015)... ... 2015 , ... BESLER Consulting today announced the firm has ... MarketingProfs Bright Bulb B2B Awards celebrate the best marketing, communications, and creative work ... their Readmissions Analytics product was selected as one of four finalists in the ...
(Date:8/3/2015)... ... August 03, 2015 , ... Novation, ... Genelex to offer pharmacogenetic lab testing and precision medicine solutions that can help ... , Annually, more than 8.6 million adverse drug events are reported in ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... retailer of nutritional supplements, has officially opened the polls for their eleventh ... the following categories:, ,     Brand of the Year (BPI ...
(Date:8/3/2015)... FL (PRWEB) , ... August 03, 2015 , ... ... to date of its industry-defining contract lifecycle management solution, as well as announced ... designed to increase the speed and ease of contract management tasks as well ...
(Date:8/3/2015)... ... August 03, 2015 , ... AxoGen, Inc. (NASDAQ: AXGN), a leader ... present at the Wedbush Healthcare Conference on Wednesday, August 12, 2015 at 9:45am (ET) ... archived replay of the Company’s presentation may be accessed via the investor relations section ...
Breaking Medicine News(10 mins):Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 2Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 3Health News:Novatus Unveils Milestone Software Release 2Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2
... is thought to be the first man to have died ... Borders revealed that Norris'// home had been cordoned off. Norris ... tests conducted showed that he had died of anthrax. ... panic since anthrax is not transmitted from person to person. ...
... Officials in Nizamabad in Andhra Pradesh have hit on a ... HIV/AIDS. When thousands of residents opened their// newspapers this Independence ... the front page. ,"Earlier we distributed condoms at ... (tobacco) shops but we met with lukewarm response," said Ashok ...
... player in the Indian drug industry, has received a ... (FDA) for three// of its abbreviated new drug applications ... launching this product in the US through its exclusive ... release Wednesday. ,The FDA approvals for Cefotaxime ...
... are high in saturated and trans fats, a high ... rate of decline in thinking, learning// and memory abilities. ... for brain development and function, an imbalance of these ... brain plaques associated with Alzheimer’s disease. Previous studies have ...
... study published in the British Medical Journal, researchers at Oxford ... per cent in the consumption of common foods// containing trans ... in coronary heart disease. ,Trans fats are added ... is added to most fast foods, confectionary, sandwich spreads, and ...
... Ireland which will aim to bring some reprieve to ... the government to the tune of ?7m annually. ... checks of patient and prescription information and comparing them ... Northern Ireland has will be enabling the system, labeled ...
Cached Medicine News:Health News:High-Fat, Copper-Rich Diets Associated with Increased Rates of Cognitive Decline 2
...
Tip is bent towards port for downward irrigation. 25G x 7/8in (.50 x 16mm)...
Conforms to the convexity of the lens providing easier access to anterior capsule. Reduces pontential of corneal touch. 23G x 5/8in (.60 x 16mm)...
... designed for LASIK surgery and other types ... corneal interface and/or stromal bed. Flattened tip ... helps elevate the flap edge. Multiple ports ... (.40 x 22mm). Angled 90 degrees, 7mm ...
Medicine Products: